Pay in 4 interest-free payments of $6.57 Learn more
Ships within 48 hours · Estimated delivery Jul 28 - Aug 2
This characteristic has made it an interesting molecule for exploratory studies in regenerative medicine, sports science, and biotechnology research
Together, these three compounds address complementary mechanisms that single-peptide protocols may not fully engage
hospitalization required Maintenance of Remission: Immunomodulators (azathioprine, 6-MP, methotrexate) for steroid-dependent or frequently-relapsing disease Biologic monotherapy or combination therapy (biologic + immunomodulator) for moderate-to-severe disease Step-up or top-down approach based on disease severity, patient risk factors, and prior therapy Biologic Therapy Targets: TNF-: Infliximab (IV), adalimumab (SC), certolizumab pegol (SC) IL-12/23: Ustekinumab (IV induction, SC maintenance) Integrin: Vedolizumab (IV) IL-23: Risankizumab (IV induction, SC maintenance) JAK inhibition: Upadacitinib (oral) Surgical Management Surgery is indicated in approximately 7080% of patients with Crohns disease over their lifetime, per StatPearls
When to seek medical attention: Patients should call 999 immediately for severe allergic reactions (facial swelling, breathing difficulties, widespread rash)
